-
1
المؤلفون: Inês Pires da Silva, Tasnia Ahmed, Jennifer L. McQuade, Caroline A. Nebhan, John J. Park, Judith M. Versluis, Patricio Serra-Bellver, Yasir Khan, Tim Slattery, Honey K. Oberoi, Selma Ugurel, Lauren E. Haydu, Rudolf Herbst, Jochen Utikal, Claudia Pföhler, Patrick Terheyden, Michael Weichenthal, Ralf Gutzmer, Peter Mohr, Rajat Rai, Jessica L. Smith, Richard A. Scolyer, Ana M. Arance, Lisa Pickering, James Larkin, Paul Lorigan, Christian U. Blank, Dirk Schadendorf, Michael A. Davies, Matteo S. Carlino, Douglas B. Johnson, Georgina V. Long, Serigne N. Lo, Alexander M. Menzies
المصدر: Pires da Silva, I, Ahmed, T, McQuade, J L, Nebhan, C A, Park, J J, Versluis, J M, Serra-Bellver, P, Khan, Y, Slattery, T, Oberoi, H K, Ugurel, S, Haydu, L E, Herbst, R, Utikal, J, Pföhler, C, Terheyden, P, Weichenthal, M, Gutzmer, R, Mohr, P, Rai, R, Smith, J L, Scolyer, R A, Arance, A M, Pickering, L, Larkin, J, Lorigan, P, Blank, C U, Schadendorf, D, Davies, M A, Carlino, M S, Johnson, D B, Long, G V, Lo, S N & Menzies, A M 2022, ' Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 40, no. 10, pp. 1068-1080 . https://doi.org/10.1200/JCO.21.01701Test
مصطلحات موضوعية: Cancer Research, Lung Neoplasms, Manchester Cancer Research Centre, Oncology, ResearchInstitutes_Networks_Beacons/mcrc, Medizin, Humans, Neoplasms, Second Primary, Immunotherapy, Ipilimumab, Melanoma, Progression-Free Survival
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e76065c510604a83b0805fd88f0ad2d7Test
https://doi.org/10.1200/jco.21.01701Test -
2
المؤلفون: Céleste Lebbé, Ines Pires da Silva, Irene L.M. Reijers, Megan Lyle, Alexander M. Menzies, Alison Weppler, Shahneen Sandhu, Camille L. Gerard, Matteo S. Carlino, Joanna Mangana, Douglas B. Johnson, Patricio Serra-Bellver, Oliver Klein, James R. Patrinely, Andrew Haydon, Tasnia Ahmed, Olivier Michielin, Khang Nguyen, Claudia Trojaniello, Paul Lorigan, Allison Betof Warner, Dan Stout, Clara Allayous, Christian U. Blank, Paolo A. Ascierto, Lisa Zimmer, Serigne Lo, Georgina V. Long
المصدر: The Lancet Oncology. 22:836-847
مصطلحات موضوعية: Male, Oncology, medicine.medical_specialty, Programmed Cell Death 1 Receptor, Medizin, Ipilimumab, Pembrolizumab, Antibodies, Monoclonal, Humanized, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Atezolizumab, Positron Emission Tomography Computed Tomography, Internal medicine, medicine, Clinical endpoint, Humans, 030212 general & internal medicine, Progression-free survival, Neoplasm Metastasis, Immune Checkpoint Inhibitors, Melanoma, Aged, Retrospective Studies, business.industry, Retrospective cohort study, Middle Aged, medicine.disease, Progression-Free Survival, Nivolumab, Drug Resistance, Neoplasm, 030220 oncology & carcinogenesis, Female, business, medicine.drug
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9178dd6e7066c6eafdc578a3589333b7Test
https://doi.org/10.1016/s1470-2045Test(21)00097-8 -
3
المؤلفون: Prachi Bhave, Tasnia Ahmed, Serigne N Lo, Alexander Shoushtari, Anne Zaremba, Judith M Versluis, Joanna Mangana, Michael Weichenthal, Lu Si, Thierry Lesimple, Caroline Robert, Claudia Trojanello, Alexandre Wicky, Richard Heywood, Lena Tran, Kathleen Batty, Florentia Dimitriou, Anna Stansfeld, Clara Allayous, Julia K Schwarze, Meghan J Mooradian, Oliver Klein, Inderjit Mehmi, Rachel Roberts-Thomson, Andrea Maurichi, Hui-Ling Yeoh, Adnan Khattak, Lisa Zimmer, Christian U Blank, Egle Ramelyte, Katharina C Kähler, Severine Roy, Paolo A Ascierto, Olivier Michielin, Paul C Lorigan, Douglas B Johnson, Ruth Plummer, Celeste Lebbe, Bart Neyns, Ryan Sullivan, Omid Hamid, Mario Santinami, Grant A McArthur, Andrew M Haydon, Georgina V Long, Alexander M Menzies, Matteo S Carlino
المساهمون: Clinical sciences, Laboratory of Molecular and Medical Oncology, Internal Medicine, Faculty of Medicine and Pharmacy, Medical Oncology
المصدر: Bhave, P, Ahmed, T, Lo, S N, Shoushtari, A, Zaremba, A, Versluis, J M, Mangana, J, Weichenthal, M, Si, L, Lesimple, T, Robert, C, Trojanello, C, Wicky, A, Heywood, R, Tran, L, Batty, K, Dimitriou, F, Stansfeld, A, Allayous, C, Schwarze, J K, Mooradian, M J, Klein, O, Mehmi, I, Roberts-Thomson, R, Maurichi, A, Yeoh, H L, Khattak, A, Zimmer, L, Blank, C U, Ramelyte, E, Kähler, K C, Roy, S, Ascierto, P A, Michielin, O, Lorigan, P C, Johnson, D B, Plummer, R, Lebbe, C, Neyns, B, Sullivan, R, Hamid, O, Santinami, M, McArthur, G A, Haydon, A M, Long, G V, Menzies, A M & Carlino, M S 2022, ' Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma ', Journal for ImmunoTherapy of Cancer, vol. 10, no. 7, e004668 . https://doi.org/10.1136/jitc-2022-004668Test
مصطلحات موضوعية: Pharmacology, Cancer Research, Skin Neoplasms, Manchester Cancer Research Centre, ResearchInstitutes_Networks_Beacons/mcrc, Immunology, Programmed Cell Death 1 Receptor, Medizin, Ipilimumab, oncology, Molecular Medicine, Immunology and Allergy, Humans, CTLA-4 Antigen, Immunotherapy, immunotherapy, Prospective Studies, Melanoma, Retrospective Studies
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92b5a9d00012b0583c371b3485e31ff2Test
https://pubmed.ncbi.nlm.nih.gov/35793872Test -
4
المؤلفون: Leonie Müller-Jensen, Sarah Zierold, Judith M. Versluis, Wolfgang Boehmerle, Petra Huehnchen, Matthias Endres, Raphael Mohr, Annette Compter, Christian U. Blank, Tim Hagenacker, Friedegund Meier, Lydia Reinhardt, Anja Gesierich, Martin Salzmann, Jessica C. Hassel, Selma Ugurel, Lisa Zimmer, Patricia Banks, Lavinia Spain, Jennifer A. Soon, Tomohiro Enokida, Makoto Tahara, Katharina C. Kähler, Ruth Seggewiss-Bernhardt, Catriona Harvey, Georgina V. Long, Florian Schöberl, Louisa von Baumgarten, Thomas Hundsberger, Max Schlaak, Lars E. French, Samuel Knauss, Lucie M. Heinzerling
المصدر: European journal of cancer 175, 224-235 (2022). doi:10.1016/j.ejca.2022.08.009
مصطلحات موضوعية: Anti-LGI1 encephalitis, Cancer Research, adverse effects [Immune Checkpoint Inhibitors], Medizin, Intracellular Signaling Peptides and Proteins, Immune checkpoint inhibitor, Glioma, Herpesvirus 1, Human, Cohort Studies, chemically induced [Encephalitis], Oncology, Immune-related adverse events, Leucine, Neurotoxicity, Encephalitis, Humans, Herpetic encephalitis, ddc:610, Immunotherapy, Immune Checkpoint Inhibitors, Autoantibodies, Retrospective Studies
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0715abb42f573c59568aefdfdb61f468Test
https://pubmed.ncbi.nlm.nih.gov/36155116Test -
5
المؤلفون: Oliver J. Kennedy, Michal Kicinski, Sara Valpione, Sara Gandini, Stefan Suciu, Christian U. Blank, Georgina V. Long, Victoria G. Atkinson, Stéphane Dalle, Andrew M. Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Rutger Koornstra, Leonel Hernandez-Aya, Anna M. Di Giacomo, Alfonsus J.M. van den Eertwegh, Jean-Jacques Grob, Ralf Gutzmer, Rahima Jamal, Alexander C.J. van Akkooi, Caroline Robert, Alexander M.M. Eggermont, Paul Lorigan, Mario Mandala
المصدر: European Journal of Cancer, 165, 97-112
European Journal of Cancer, 165, pp. 97-112
Kennedy, O J, Kicinski, M, Valpione, S, Gandini, S, Suciu, S, Blank, C U, Long, G V, Atkinson, V G, Dalle, S, Haydon, A M, Meshcheryakov, A, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, Di Giacomo, A M, van den Eertwegh, A J M, Grob, J J, Gutzmer, R, Jamal, R, van Akkooi, A C J, Robert, C, Eggermont, A M M, Lorigan, P & Mandala, M 2022, ' Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma ', European Journal of Cancer, vol. 165, pp. 97-112 . https://doi.org/10.1016/j.ejca.2022.01.017Testمصطلحات موضوعية: Cancer Research, Skin Neoplasms, Adrenergic beta-Antagonists, Medizin, Antibodies, Monoclonal, Humanized, Adrenergic beta-antagonists, Beta-blockers, Immunomodulation, Immunotherapy, Melanoma, Adjuvants, Immunologic, Humans, Neoplasm Staging, Prognosis, Tumor Microenvironment, Antibodies, Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], All institutes and research themes of the Radboud University Medical Center, Immunologic, Monoclonal, Adjuvants, Humanized, Manchester Cancer Research Centre, ResearchInstitutes_Networks_Beacons/mcrc, Oncology
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d75ba607dbd7225632c8df9aab98b7d3Test
http://hdl.handle.net/2066/250190Test -
6
المؤلفون: Rutger H. T. Koornstra, Sandrine Marreaud, Victoria Atkinson, Andrey Meshcheryakov, Christian U. Blank, Piotr Rutkowski, Jean-Jacques Grob, Leonel Hernandez-Aya, Clemens Krepler, Michal Kicinski, Dirk Schadendorf, Paolo A. Ascierto, Caroline Robert, Mario Mandalà, Susana Puig, Nageatte Ibrahim, Alexander C.J. van Akkooi, Adnan Khattak, Stéphane Dalle, Georgina V. Long, James Larkin, Shahneen Sandhu, Rahima Jamal, Matteo S. Carlino, Alfonsus J M van den Eertwegh, Ralf Gutzmer, Anna Maria Di Giacomo, Andrew Haydon, Alexander M.M. Eggermont, Stefan Suciu, Paul Lorigan
المساهمون: CCA - Cancer Treatment and quality of life, Medical oncology
المصدر: Journal of Clinical Oncology, 38, 3925-3936
Eggermont, A M M, Blank, C U, Mandala, M, Long, G V, Atkinson, V G, Dalle, S, Haydon, A M, Meshcheryakov, A, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, di Giacomo, A M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P C, van Akkooi, A C J, Krepler, C, Ibrahim, N, Marreaud, S, Kicinski, M, Suciu, S & Robert, C 2020, ' Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial ', Journal of Clinical Oncology, vol. 38, no. 33, pp. 3925-3936 . https://doi.org/10.1200/JCO.20.02110Test
Journal of Clinical Oncology, 38(33), 3925-3936. American Society of Clinical Oncology
Journal of Clinical Oncology
Eggermont, A M M, Blank, C U, Mandala, M, Long, G V, Atkinson, V G, Dalle, S, Haydon, A M, Meshcheryakov, A, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, Di Giacomo, A M, van den Eertwegh, A J M, Grob, J J, Gutzmer, R, Jamal, R, Lorigan, P C, van Akkooi, A C J, Krepler, C, Ibrahim, N, Marreaud, S, Kicinski, M, Suciu, S & Robert, C 2020, ' Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma : Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 38, no. 33, pp. 3925-3936 . https://doi.org/10.1200/JCO.20.02110Test
Journal of Clinical Oncology, 38, 33, pp. 3925-3936مصطلحات موضوعية: 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, Medizin, Pembrolizumab, Placebo, law.invention, Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, 0302 clinical medicine, Randomized controlled trial, law, Internal medicine, Original Reports, medicine, Stage III melanoma, Melanoma, Chemotherapy, Manchester Cancer Research Centre, business.industry, ResearchInstitutes_Networks_Beacons/mcrc, Cancer, medicine.disease, Clinical trial, 030104 developmental biology, 030220 oncology & carcinogenesis, business, Adjuvant
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19c8d8800862ec580f808001677c9a85Test
https://hdl.handle.net/2066/228545Test -
7
المؤلفون: Christian U. Blank, Stéphane Dalle, Alexander M.M. Eggermont, Sandrine Marreaud, Matteo S. Carlino, Alfonsus J. M. van den Eertwegh, Stefan Suciu, Nageatte Ibrahim, Rahima Jamal, Paolo A. Ascierto, Alexander C.J. van Akkooi, Michal Kicinski, Piotr Rutkowski, Georgina V. Long, Dirk Schadendorf, Ralf Gutzmer, Shahneen Sandhu, Andrew Haydon, Victoria Atkinson, Susana Puig, Adnan Khattak, Anna Maria Di Giacomo, Clemens Krepler, Mario Mandalà, Rutger H. T. Koornstra, Caroline Robert, Jean-Jacques Grob, Leonel Hernandez-Aya, Paul Lorigan, James Larkin
المساهمون: Medical oncology, CCA - Cancer Treatment and quality of life, AII - Cancer immunology
المصدر: Jama Oncology, 6, 519-527
Eggermont, A M M, Kicinski, M, Blank, C U, Mandala, M, Long, G V, Atkinson, V, Dalle, S, Haydon, A, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, di Giacomo, A M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P C, Krepler, C, Ibrahim, N, Marreaud, S, van Akkooi, A, Robert, C & Suciu, S 2020, ' Association between Immune-Related Adverse Events and Recurrence-Free Survival among Patients with Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial ', JAMA Oncology, vol. 6, no. 4, pp. 519-527 . https://doi.org/10.1001/jamaoncol.2019.5570Test
Eggermont, A M M, Kicinski, M, Blank, C U, Mandala, M, Long, G V, Atkinson, V, Dalle, S, Haydon, A, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, Di Giacomo, A M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P C, Krepler, C, Ibrahim, N, Marreaud, S, van Akkooi, A, Robert, C & Suciu, S 2020, ' Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo : A Secondary Analysis of a Randomized Clinical Trial ', JAMA oncology . https://doi.org/10.1001/jamaoncol.2019.5570Test
Jama Oncology, 6, 4, pp. 519-527
JAMA Oncology, 6(4), 519-527. American Medical Associationمصطلحات موضوعية: Adult, Male, Cancer Research, medicine.medical_specialty, Population, Medizin, Pembrolizumab, Placebo, Antibodies, Monoclonal, Humanized, Disease-Free Survival, law.invention, Placebos, Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, 0302 clinical medicine, Randomized controlled trial, Double-Blind Method, law, Internal medicine, Medicine, Humans, 030212 general & internal medicine, education, Adverse effect, Melanoma, Aged, Neoplasm Staging, Proportional Hazards Models, education.field_of_study, Manchester Cancer Research Centre, business.industry, Proportional hazards model, ResearchInstitutes_Networks_Beacons/mcrc, Hazard ratio, Middle Aged, Ipilimumab, Clinical trial, Oncology, 030220 oncology & carcinogenesis, Female, Neoplasm Recurrence, Local, business
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9b431bc34ae329792ac7bd923376806Test
https://hdl.handle.net/2066/218502Test -
8
المؤلفون: Sanne Patiwael, Christian U. Blank, Ton N. Schumacher, Antoni Ribas, John B. A. G. Haanen, Anastasia Gangaev, Daisy Philips, Dirk Schadendorf, Joost H. van den Berg, Maartje W. Rohaan, Bastian Schilling, Elisa A. Rozeman, Pia Kvistborg, Olga I. Isaeva
المصدر: Proc Natl Acad Sci U S A
Proceedings of the National Academy of Sciences of the United States of America, vol 118, iss 43مصطلحات موضوعية: Male, Receptors, Antigen, T-Cell, alpha-beta, Programmed Cell Death 1 Receptor, Medizin, Epitopes, T-Lymphocyte, CD8-Positive T-Lymphocytes, Lymphocyte Activation, Epitope, Cohort Studies, Epitopes, melanoma-reactive CD8 T cells, Receptors, PD-1, 80 and over, Cytotoxic T cell, CTLA-4 Antigen, Hepatitis A Virus Cellular Receptor 2, Immune Checkpoint Inhibitors, Melanoma, Cancer, alpha-beta, Aged, 80 and over, Multidisciplinary, Middle Aged, Biological Sciences, medicine.anatomical_structure, 5.1 Pharmaceuticals, Antigen, Female, Development of treatments and therapeutic interventions, medicine.symptom, Melanoma-Specific Antigens, Adult, Receptors, CXCR5, T cell, In Vitro Techniques, Clinical Research, medicine, Humans, Aged, business.industry, Compartment (ship), T-Cell, medicine.disease, CXCR5, Blockade, Kinetics, T-Lymphocyte, Mechanism of action, CTLA-4, Cancer research, business
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::994323e563648a11d8ffa0127b701604Test
https://doi.org/10.1073/pnas.2102849118Test -
9
المؤلفون: Christoph Hoeller, Marie-Francoise Avril, Pietro Quaglino, François Aubin, Lars Bastholt, Takashi Inozume, Virginia Ferraresi, Michael B. Jameson, Kevin B. Kim, Oliver Bechter, Dirk Schadendorf, Kenji Yokota, Carmen Loquai, Maria-Jose Passos, Inge Marie Svane, Michele Maio, Catherine Barrow, Frank Meiss, Nageatte Ibrahim, Andrzej Mackiewicz, Phillip Parente, Tatsuya Takenouchi, Caroline Dutriaux, Piotr Rutkowski, Alfonsus J M van den Eertwegh, Paola Queirolo, Catriona M. McNeil, Peter Mohr, Felix Kiecker, Susana Puig, Friedegund Meier, Lutz Kretschmer, Alexander C.J. van Akkooi, Alex Menzies, Timothy Crook, Christian U. Blank, Suzana Matkovic, Michael C. Brown, Ragini R. Kudchadkar, Max Levin, Rüdiger Hein, Tanja Skytta, Gerald P. Linette, Clemens Krepler, Adnan Khattak, Ernest Marshall, Joseph Kerger, Oddbjorn Straume, Laurent Mortier, Jochen Utikal, Micaela Hernberg, James Larkin, Yoshio Kiyohara, Mario Mandalà, Henrik Schmidt, Daniil Stroyakovskiy, Pablo Luis Ortiz Romero, Naoya Yamazaki, John Walker, Anna Maria Di Giacomo, Lionel Geoffrois, Jean-Philippe Lacour, Caroline Robert, Vincent Descamps, Shahneen Sandhu, Gil Bar-Sela, Paul C. Nathan, Marcin Dzienis, Ralf Gutzmer, Claus Garbe, Andrey Meshcheryakov, Patrick Combemale, Martin Fehr, Guzel Mukhametshina, Helena Kapiteijn, Geke A. P. Hospers, Jun Aoi, Andrew Haydon, Rutger H. T. Koornstra, Marie-Thérèse Leccia, Sigrun Hallmeyer, Pier Francesco Ferrucci, Jean-Jacques Grob, Leonel Hernandez-Aya, Jan-Christoph Simon, Vanna Chiarion Sileni, Alain Algazi, Lidija Sekulovic, Sandrine Marreaud, Bernard Fitzharris, Jacob Schachter, Xinni Song, Wolf-Henning Boehncke, Rahima Jamal, Paul Lorigan, Maureen J.B. Aarts, Reinhard Dummer, Mike McCrystal, César Martins, Reiner Hofmann-Wellenhof, Alexander M.M. Eggermont, Carola Berking, Elaine Dunwoodie, Bernard Guillot, Michal Kicinski, Philippe Saiag, Céleste Lebbé, Thierry Lesimple, Stefan Suciu, Michal Lotem, Paula Ferreira, Mohammed M. Milhem, Laurent Machet, Patrick Terheyden, Anna Katharina Winge-Main, Peter Hersey, Jean-Francois Baurain, Axel Hauschild, Stéphane Dalle, Jean-Philippe Arnault, Paolo A. Ascierto, Gerard Groenewegen, Florent Grange, Georgina V. Long, Victoria Atkinson, Philippa Corrie, Matteo S. Carlino, Thomas Jouary, Daniel Hendler, Richard Casasola, Ashita Waterston, Jessica C. Hassel
المساهمون: University Medical Center [Utrecht], Azienda Ospedaliera Ospedale Papa Giovanni XXIII [Bergamo, Italy], The University of Sydney, Princess Alexandra Hospital, Brisbane, University of Queensland [Brisbane], Centre Léon Bérard [Lyon], Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), N.N. Blokhin National Medical Research Center of Oncology, Edith Cowan University (ECU), Royal Marsden NHS Foundation Trust, Universitat de Barcelona (UB), Instituto de Salud Carlos III [Madrid] (ISC), Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology (MCMCC), Universitätsklinikum Essen [Universität Duisburg-Essen] (Uniklinik Essen), Radboud University Medical Center [Nijmegen], Washington University School of Medicine in St. Louis, Washington University in Saint Louis (WUSTL), University Hospital of Siena, Amsterdam UMC - Amsterdam University Medical Center, Hôpital de la Timone [CHU - APHM] (TIMONE), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hannover Medical School [Hannover] (MHH), Centre Hospitalier de l'Université de Montréal (CHUM), Université de Montréal (UdeM), The Christie NHS Foundation Trust [Manchester, Royaume-Uni], Merck & Co. Inc, European Organisation for Research and Treatment of Cancer [Bruxelles] (EORTC), European Cancer Organisation [Bruxelles] (ECCO), Institut Gustave Roussy (IGR), Oncologie dermatologique, Département de médecine oncologique [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Université de Montpellier (UM), Internal medicine, CCA - Cancer Treatment and quality of life
المصدر: EORTC Melanoma Group 2021, ' Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial ', The Lancet Oncology, vol. 22, no. 5, pp. 643-654 . https://doi.org/10.1016/S1470-2045Test(21)00065-6
Lancet Oncology, 22, 643-654
Lancet Oncology, 22, 5, pp. 643-654
Lancet Oncology
Lancet Oncology, 2021, 22 (5), pp.643-654. ⟨10.1016/S1470-2045(21)00065-6⟩
The Lancet Oncology, 22(5), 643-654. Lancet Publishing Groupمصطلحات موضوعية: Male, Skin Neoplasms, Medizin, Pembrolizumab, law.invention, Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], MESH: Aged, 80 and over, 0302 clinical medicine, Randomized controlled trial, law, Monoclonal, 80 and over, MESH: Double-Blind Method, 030212 general & internal medicine, Neoplasm Metastasis, Humanized, Melanoma, MESH: Aged, Aged, 80 and over, education.field_of_study, MESH: Middle Aged, Hazard ratio, MESH: Neoplasm Staging, Middle Aged, Oncology, 030220 oncology & carcinogenesis, Female, Adult, Aged, Antibodies, Monoclonal, Humanized, Double-Blind Method, Humans, Neoplasm Staging, medicine.medical_specialty, MESH: Melanoma, Population, [SDV.CAN]Life Sciences [q-bio]/Cancer, Placebo, Antibodies, 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, Internal medicine, medicine, Adjuvant therapy, education, Cancer staging, MESH: Humans, business.industry, MESH: Skin Neoplasms, MESH: Adult, MESH: Neoplasm Metastasis, MESH: Male, Clinical trial, MESH: Antibodies, Monoclonal, Humanized, business, MESH: Female
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca46af8de45fdf5ffd9d70f717e94208Test
https://research.vumc.nl/en/publications/8aae177c-dfa8-4325-b8c2-e7b1d7339027Test -
10
المؤلفون: Thomas Eigentler, Cindy Franklin, Anja Gesierich, Claus Garbe, Sebastian Haferkamp, James Larkin, Sophia Kreft, Paul Lorigan, Bastian Schilling, Sara Valpione, Selma Ugurel, Jochen Utikal, Dirk Schadendorf, Christian U. Blank
المصدر: European Journal of Cancer. 116:207-215
مصطلحات موضوعية: Adult, Male, 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Skin Neoplasms, medicine.medical_treatment, Programmed Cell Death 1 Receptor, Medizin, Ipilimumab, Pembrolizumab, Antibodies, Monoclonal, Humanized, Targeted therapy, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Internal medicine, medicine, Humans, Molecular Targeted Therapy, Adverse effect, Melanoma, Aged, Retrospective Studies, Aged, 80 and over, Salvage Therapy, business.industry, Immunotherapy, Middle Aged, medicine.disease, Confidence interval, Nivolumab, Treatment Outcome, 030104 developmental biology, Drug Resistance, Neoplasm, 030220 oncology & carcinogenesis, Female, Neoplasm Recurrence, Local, business, medicine.drug
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0f33bef3ecdaf233f4184cbdb0bbc1eTest
https://doi.org/10.1016/j.ejca.2019.05.015Test